Navigation Links
Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results
Date:6/18/2010

SHENZHEN, China, June 18 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese Medicines Company (the "Company" or "Tongjitang") (NYSE: TCM), a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended March 31, 2010.

    Financial Results for the Quarter Ended March 31, 2010

    -- Net revenue increased 25.6% to RMB 113.3 million ($16.6 million)
       (note 1), from RMB 90.2 million in the prior year period.
    -- Operating loss was RMB 9.7 million ($1.4 million), compared to an
       operating loss of RMB 10.3 million in the prior year period.
    -- Net loss attributable to the Company was RMB 13.4 million ($2.0
       million), which yielded net loss per ADS of RMB 0.52 ($0.08) and net
       loss per share(note 2) of RMB 0.13 ($0.02).
    -- Non-GAAP loss per share was RMB 0.04 ($0.01), compared to non-GAAP loss
       per share of RMB 0.01 in the first quarter of 2009.

Xiaochun Wang, Chief Executive Officer and Chairman of Tongjitang, stated, "Our first quarter performance reflects strong revenue improvement in our pharmaceutical business. During the first quarter, we expanded our sales networks into community hospitals to better align ourselves with the government's reform efforts, which focused on rural areas. Even though the pace of National Essential Drug List ("EDL") implementation by the local governments has been much slower than expected, we anticipate a notable increase in sales of EDL drugs beginning in the later part of this year."


'/>"/>
SOURCE Tongjitang Chinese Medicines Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Tongjitang Chinese Medicines Acquires Guiyang Liquor Factory
2. Biosites Triage Products Seized by Beijing Customs; Chinese Market Facing Shortage
3. China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology
4. Chinese Distribution Contract Extended for an Additional 4 Years
5. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
7. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
8. Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World
9. GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms
10. Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Neurotrope Bioscience, Inc., ... a world-wide, exclusive license agreement with the Icahn School ... ( Mount Sinai ) to utilize its ... Bryostatin-1 in the treatment of Niemann-Pick Type C Disease ... afflicted with Alzheimer-like symptoms. The license also covers other ...
(Date:7/22/2014)... , July 22, 2014 WuXi PharmaTech (Cayman) ... and medical device R&D outsourcing company with operations in ... , today announced that it will release financial results ... Stock Exchange closes on Wednesday, August 13, 2014 (which will ... release will be available on the investor relations section of ...
(Date:7/22/2014)... July 22, 2014  UL (Underwriters Laboratories), a ... U.S. Food and Drug Administration (FDA) has recognized ... for medical devices incorporating lithium or nickel-based batteries. ... for Household and Commercial Batteries, and UL 1642 ... Consensus standards are standards recognized by the ...
Breaking Medicine Technology:Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2
... 6, 2011 A new study , released ... the United States witnessed opiate prescriptions for chronic abdominal ... Michael Lowenstein, co-medical director for the Waismann Method, an ... that this increase signals the gaining popularity of prescription ...
...  Glowpoint, Inc. (OTCBB: GLOW), a leading global provider of ... a leading global pharmaceutical services company has signed with ...   This new Glowpoint customer is the ... clinical, commercial, consulting and capital solutions. The firm has ...
Cached Medicine Technology:Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 2Rise in Opioid Use for Abdominal Pain Points to Larger Problem Warns Waismann Method Medical Director 3Global Pharmaceutical Services Company Turns to Glowpoint's OpenVideo™ Cloud 2
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... Society of Hematology (ASH) will honor Tomas Ganz, MD, ... with the 2014 E. Donnall Thomas Lecture for his ... the iron-regulatory hormone hepcidin and investigation of its roles ... Prize Laureate and past Society president E. Donnall Thomas, ... represented a paradigm shift or significant discovery in the ...
(Date:7/22/2014)... at the University of Utah,s John A. Moran Eye ... Eye Research (ISER) as the recipient of the Houston, ... in Retina Research., The award recognizes lifetime achievement by ... to the understanding of vitreoretinal diseases or disorders. The ... Biennial Meeting in San Francisco, where Marc will deliver ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC News, ... favorite beauty products, “ Botox , that’s pretty much it.” ... has changed my life” by halving the amount of ... various, daily appearances. “Suddenly my eyelids are no longer ... “I think that Kelly Ripa’s response to the question was ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... Dr. Lawyer will lead clinical efforts of the ... KePRO, a national medical,management firm, appointed Lenaye ... Dr. Lawyer will oversee all clinical aspects of ... Harrisburg,office., "Dr. Lawyer has practiced her entire ...
... the Northeast region with more hires,planned throughout the ... Aug. 28 The Pennsylvania,Patient Safety Authority has ... to help healthcare facilities that report to the,Pennsylvania ... Pennsylvania citizens., "Last year in focus groups ...
... 67%, but patients and doctors say drug is hard to ... percent of patients with atrial fibrillation, a known risk factor ... anti-clotting drug warfarin, a new study found. , Among those ... prevent a stroke. And an additional 25 percent were taking ...
... growing professional and consumer markets in China. , ... ... international venture capital firm, today announced that together with Mustang Ventures, ... of financing for Profex.Inc. Trident Capital & Mustang Ventures jointly invested ...
... HAYWARD, Calif., Aug. 28 Guava Technologies, Inc.,announced ... Group to,provide drug discovery researchers with an automated ... key component of a larger,strategic initiative by Guava ... voiced need for sophisticated cell analysis technology to,support ...
... increased plaque , , THURSDAY, Aug. 28 (HealthDay News) -- A ... in the brain that is thought to play a key ... the protein, known as amyloid beta, was directly linked to ... When brain cell communication increased, so did amyloid beta. When ...
Cached Medicine News:Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
Inquire...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
Medicine Products: